Gen­mab steps up for a $500M IPO haul, with its sights on a record-set­ting mar­ket cap

Gen­mab is right on the thresh­old now of com­plet­ing the largest biotech list­ing — by mar­ket cap — that Re­nais­sance Cap­i­tal has seen for the past 20 years or more.

The Copen­hagen-based com­pa­ny has set its terms for a Nas­daq de­but, plan­ning to sell 27.8 mil­lion shares at $18.11 a share — the val­ue of their stock as of the close on Fri­day. That would give them a mar­ket cap of $11.8 bil­lion, which is a rare sight on Wall Street.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.